[go: up one dir, main page]

SG11202102441VA - Imidazopyridinone compound - Google Patents

Imidazopyridinone compound

Info

Publication number
SG11202102441VA
SG11202102441VA SG11202102441VA SG11202102441VA SG11202102441VA SG 11202102441V A SG11202102441V A SG 11202102441VA SG 11202102441V A SG11202102441V A SG 11202102441VA SG 11202102441V A SG11202102441V A SG 11202102441VA SG 11202102441V A SG11202102441V A SG 11202102441VA
Authority
SG
Singapore
Prior art keywords
imidazopyridinone
compound
imidazopyridinone compound
Prior art date
Application number
SG11202102441VA
Other languages
English (en)
Inventor
Akihiro Moriyama
Yasushi Takigawa
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of SG11202102441VA publication Critical patent/SG11202102441VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
SG11202102441VA 2018-09-13 2019-09-12 Imidazopyridinone compound SG11202102441VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018171839 2018-09-13
PCT/JP2019/035792 WO2020054788A1 (ja) 2018-09-13 2019-09-12 イミダゾピリジノン化合物

Publications (1)

Publication Number Publication Date
SG11202102441VA true SG11202102441VA (en) 2021-04-29

Family

ID=69777067

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102441VA SG11202102441VA (en) 2018-09-13 2019-09-12 Imidazopyridinone compound

Country Status (20)

Country Link
US (2) US12077531B2 (he)
EP (1) EP3808747B1 (he)
JP (1) JP7458987B2 (he)
KR (1) KR20210057014A (he)
CN (1) CN112689637B (he)
AR (1) AR116400A1 (he)
AU (1) AU2019340173B2 (he)
BR (1) BR112021004730A2 (he)
CA (1) CA3106385A1 (he)
DK (1) DK3808747T3 (he)
FI (1) FI3808747T3 (he)
IL (1) IL281391B2 (he)
MX (1) MX2021003027A (he)
PH (1) PH12021550512A1 (he)
PL (1) PL3808747T3 (he)
PT (1) PT3808747T (he)
SG (1) SG11202102441VA (he)
TW (1) TWI814903B (he)
WO (1) WO2020054788A1 (he)
ZA (1) ZA202101671B (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414550B2 (ja) * 2020-01-23 2024-01-16 キッセイ薬品工業株式会社 (ヘテロ)アリールイミダゾロン化合物
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2021182490A1 (ja) * 2020-03-11 2021-09-16 キッセイ薬品工業株式会社 イミダゾピリジノン化合物又はその塩の結晶
JP7654426B2 (ja) 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101421T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
KR20010085824A (ko) 1998-09-18 2001-09-07 스타르크, 카르크 단백질 키나아제 억제제로서의 피롤로피리미딘
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
AU2004259736A1 (en) * 2003-07-23 2005-02-03 Wyeth Sulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
KR100907354B1 (ko) * 2004-05-18 2009-07-10 쉐링 코포레이션 Pde4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸
EP1861377B1 (en) 2005-03-15 2010-12-29 Pfizer, Inc. Benzimidazolone derivatives as cb2 receptor ligands
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007015877A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
CA2634235A1 (en) 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
JP2010503654A (ja) 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
WO2008144266A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
MX2009012612A (es) * 2007-05-23 2009-12-07 Pharmacopeia Llc Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
CA2698071A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
CN101951777A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢呋喃并吡啶酮
WO2009134754A1 (en) * 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
EP2285375B1 (en) 2008-05-08 2013-04-10 Merck Sharp & Dohme Corp. spiroazaindole compounds as HIF propylhydroxylase inhibitors
EP2364313B1 (en) * 2008-09-09 2014-01-08 Boehringer Ingelheim International GmbH Aza-benzimidazolone chymase inhibitors
KR101706803B1 (ko) 2009-07-17 2017-02-14 니뽄 다바코 산교 가부시키가이샤 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용
JP2011037814A (ja) 2009-08-14 2011-02-24 Synstar Japan Co Ltd マラリア原虫疾患予防又は治療用の5−ヘテロ環置換イミノ−9−ジアルキルアミノベンゾ[a]フェノキサチン化合物又はその塩とアーテミシニン誘導体との組み合わせ
WO2011096490A1 (ja) 2010-02-04 2011-08-11 第一三共株式会社 イミダゾピリジン-2-オン誘導体
FR2967355B1 (fr) * 2010-11-17 2013-09-27 Jouvin Jean Luc Seringue dentaire securisee
WO2014181813A1 (ja) 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
US10025430B2 (en) 2013-10-08 2018-07-17 Maxell, Ltd. Projection type image display device, manipulation detection device and projection type image display method
SG11201604755QA (en) 2013-10-10 2016-07-28 Glenmark Pharmaceuticals Sa Substituted dihydro-benzimidazole compounds as ror gamma modulators
CN104926733B (zh) * 2014-03-18 2019-05-10 北京韩美药品有限公司 作为RORγ调节剂的化合物
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
PH12021551681A1 (en) * 2015-06-03 2023-08-23 Prinicipia Biopharma Inc Tyrosine kinase inhibitors
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
AU2017317123B9 (en) * 2016-08-22 2021-11-25 Medshine Discovery Inc. PDE4 inhibitor
TWI757340B (zh) * 2016-09-16 2022-03-11 美商生命醫藥有限責任公司 梅嫩蛋白(menin)-MLL相互作用之抑制劑
CN111615513A (zh) * 2018-01-19 2020-09-01 爱杜西亚药品有限公司 C5a受体调节剂

Also Published As

Publication number Publication date
CA3106385A1 (en) 2020-03-19
FI3808747T3 (fi) 2025-02-07
DK3808747T3 (da) 2025-02-03
CN112689637A (zh) 2021-04-20
IL281391A (he) 2021-04-29
EP3808747A4 (en) 2022-03-09
KR20210057014A (ko) 2021-05-20
US12077531B2 (en) 2024-09-03
ZA202101671B (en) 2022-07-27
WO2020054788A1 (ja) 2020-03-19
EP3808747A1 (en) 2021-04-21
PT3808747T (pt) 2025-01-30
AU2019340173B2 (en) 2024-02-08
CN112689637B (zh) 2023-11-10
TW202024077A (zh) 2020-07-01
AR116400A1 (es) 2021-05-05
EP3808747B1 (en) 2024-12-18
PL3808747T3 (pl) 2025-03-17
IL281391B1 (he) 2024-12-01
US20240425504A1 (en) 2024-12-26
JP7458987B2 (ja) 2024-04-01
JPWO2020054788A1 (ja) 2021-08-30
TWI814903B (zh) 2023-09-11
AU2019340173A1 (en) 2021-04-08
IL281391B2 (he) 2025-04-01
MX2021003027A (es) 2021-05-27
PH12021550512A1 (en) 2022-02-21
BR112021004730A2 (pt) 2021-06-01
US20210206765A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
GB201806578D0 (en) Novel compound
PL3827042T3 (pl) Związek wielo-azyrydynowy
GB201810092D0 (en) Compounds
GB201805174D0 (en) Compounds
GB201801355D0 (en) Compounds
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
ZA202101671B (en) Imidazopyridinone compound
GB201808093D0 (en) Compounds
GB201814151D0 (en) Compounds
GB201812382D0 (en) Compounds
GB201809102D0 (en) Compounds
GB201818649D0 (en) Compounds
GB201818651D0 (en) Compounds
GB201817083D0 (en) Compounds
GB201810071D0 (en) Compounds
GB201803340D0 (en) Compounds
GB201814167D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201801130D0 (en) Compounds
GB201819102D0 (en) Compounds
GB201818927D0 (en) Compounds
GB201818698D0 (en) Compounds
GB201818410D0 (en) Compounds
GB201817342D0 (en) Compounds